Long-term outcomes for patients with Hodgkin lymphoma at increased risk of progression or relapse

Abstract

Although advancements in the treatment of Hodgkin lymphoma have enabled many patients to be cured of their disease, about half of patients who relapse or experience refractory disease ultimately fail treatment, even after autologous stem cell transplant. Risk stratification is crucial to enable escalation of therapy in patients at increased risk for progression while allowing for less intensive therapy in lower risk groups. Utilization of clinical factors to inform risk scores was common practice, but this historical approach has been supplemented by PET/CT risk adapted management. Long-term outcomes of high-risk patients have improved over the decades with advancements in therapy and emergence of novel agents including antibody-drug conjugates and immune checkpoint inhibitors, yet further research is urgently needed. Herein, we review long-term outcomes of patients with Hodgkin lymphoma at increased risk for progression or relapse and discuss limitations of current risk strategies.

Keywords:

• Hodgkin lymphoma
• risk stratification
• long-term outcomes

Disclosure statement

SMA receives research funding for clinical trials (paid to his institution) from Bristol Myers Squibb, Takeda, SeaGen, Regeneron, Pfizer, AstraZeneca, and ADC Therapeutics. SK has no conflicts of interest.

Additional information

Funding

No author received any specific funding or support for this work.